je.st
news
New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
2014-11-06 15:08:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
the
time
first
Category:Biotechnology and Pharmaceuticals